A5034571654- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Pancreatitis Pathology and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal cell carcinoma treatment
- Neuroendocrine Tumor Research Advances
- Inflammatory Bowel Disease
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Liver Disease Diagnosis and Treatment
- Liver Diseases and Immunity
- Organ Transplantation Techniques and Outcomes
- Microscopic Colitis
- Gastric Cancer Management and Outcomes
- Synthesis and Reactions of Organic Compounds
- Mycobacterium research and diagnosis
- Bioactive Compounds and Antitumor Agents
- Surgical Simulation and Training
- Eosinophilic Esophagitis
- Gastrointestinal disorders and treatments
- Inflammatory Biomarkers in Disease Prognosis
- Biliary and Gastrointestinal Fistulas
- Viral-associated cancers and disorders
Asan Medical Center
2021-2025
University of Ulsan
2021-2024
Ulsan College
2021-2024
Seoul National University Hospital
2019-2022
Seoul National University
2017-2021
Korean Cancer Study Group
2021
New Generation University College
2019
Abstract Background FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC). However, evidence is lacking comparing not only two regimens, but also sequential treatment (FFX–GnP vs. GnP–FFX). Methods Data of 528 patients (FFX, n = 371; GnP, 157) with mPC were collected retrospectively. Propensity score matching was conducted to alleviate imbalance groups. Overall survival (OS), progression free...
<title>Abstract</title> Background Portal vein embolization (PVE) is often recommended to avoid postoperative liver failure and subsequent mortality after surgical resection of perihilar cholangiocarcinoma (CCA). However, evidence its effect on outcomes long-term survival limited. Methods We retrospectively reviewed the data 137 patients diagnosed with Bismuth type III–IV CCA between April 2011 August 2021. Among patients, 88 were included in analyses divided into three groups: without PVE...
Abstract Background and Objectives Recurrence of benign bilioenteric anastomotic strictures (BAS) is common after enteroscopy-assisted endoscopic retrograde cholangiopancreatography (ERCP), percutaneous intervention, or EUS-guided antegrade intervention (EUS-AI). This study evaluated the long-term outcomes EUS-AI with transmural transanastomotic stenting (TAS) following hepaticogastrostomy (HGS) in BAS. Methods Consecutive patients BAS undergoing without TAS failed deep enteroscopy between...
Gallbladder cancer (GBC) is likely to be diagnosed at progressive stages and shows a very poor prognosis. Combination therapy with gemcitabine cisplatin (GEMCIS) has been widely used as first-line palliative chemotherapy for advanced GBC. This study was designed investigate the efficacy of GEMCIS identify prognostic factors in patients unresectable GBC.Patients GBC who were treated from January 2008 June 2017 single tertiary hospital included. All cases by pathologic findings extent tumour...
Recurrent pyogenic cholangitis (RPC) is a chronic progressive disease frequently accompanied by cholangiocarcinoma (CCA). This study aimed to investigate the natural course of RPC and identify factors associated with CCA.From January 2005 December 2016, 310 patients diagnosed at Seoul National University Hospital were included. Complications management during follow-up recorded. CCA-free probability was estimated Kaplan-Meier method, risk CCA analyzed using log-rank test Coxs proportional...
Abstract Background Several systemic inflammatory response (SIR) markers, including platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and albumin-to-globulin (AGR), have emerged as prognostic markers in various cancers. The aim of this study was to explore the impact SIR on survival outcomes unresectable intrahepatic cholangiocarcinoma (IHC) patients. Methods Patients with histologically confirmed, IHC treated gemcitabine plus cisplatin (GP)...
Background The use of biologics in inflammatory bowel disease (IBD) has increased recently. However, studies on whether the proportion IBD patient visits to emergency department (ED) decreased are scarce. We investigated trends IBD-related ED and hospitalization rates. Methods Medical records ambulatory (AD) Seoul National University Bundang Hospital 2007, 2009, 2012, 2014 were reviewed. Multiple-variable logistic regression analysis was used identify significant risk factors for...
Abstract Background Although several studies have suggested that aspirin and statins may help prevent pancreatic ductal adenocarcinoma (PDAC), this concept has been controversial. This study aimed to evaluate the association between use of statin or PDAC in a nationwide large cohort. Methods In nested case‐control study, we used data from 12‐year longitudinal cohort Korea. Cases with controls who were matched cases by age, sex, income, index year at 1:5 ratio established. We multivariate...
Abstract Background There is a lack of studies regarding the optimal timing for endoscopic retrograde cholangiopancreatography (ERCP) in patients with cholangitis caused by distal malignant biliary obstruction (MBO). This study aims to investigate ERCP acute associated MBO naïve papilla. Methods A total 421 cholangitis, MBO, were enrolled this study. An urgent was defined as being an performed within 24 h following emergency room (ER) arrival, and early between 48 ER arrival. We evaluated...
A clinical unmet need persists for medications capable of modulating the progression primary sclerosing cholangitis (PSC). This study aimed to assess feasibility HK-660S (beta-lapachone) in PSC.
Background and aims Pancreatic ductal adenocarcinoma (PDAC) often presents as acute pancreatitis (AP). However, data on the clinical outcomes of PDAC initially presenting AP are limited. We aimed to assess features that manifest AP.
Background: The aim of this study was to evaluate the efficacy and safety gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy following first-line FOLFIRINOX treatment failure in advanced pancreatic cancer. Methods: This a multicenter, single-arm, open-label, phase 2 trial done at three tertiary centers South Korea from May 2018 December 2019. Eligible patients were aged 20 years or older, had histologically confirmed ductal adenocarcinoma, disease progression after receiving...
The combination of nab-paclitaxel and gemcitabine (nab-P/Gem) is widely used for treating metastatic pancreatic cancer (MPC). We aimed to evaluate the therapeutic outcomes prognostic role treatment-related peripheral neuropathy in patients with MPC treated nab-P/Gem clinical practice.MPC as first-line chemotherapy were included. All 88 Korean underwent at least two cycles (125 1,000 mg/m2, respectively). Treatment-related adverse events monitored through periodic follow-ups. Overall survival...
The adjuvant treatment for patients with resected pancreatic cancer (PC) is not yet standardized. Because the prognosis differs according to American Joint Committee on Cancer (AJCC) stage, a tailored approach establish more aggressive plans in high-risk necessary. However, studies comparing efficacy of modalities AJCC stage are largely lacking.To compare chemotherapy and chemoradiation therapy 8th staging system PC who underwent surgical resection.A total 335 resection were included....
Abstract Background Nafamostat mesilate decreases the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). However, no studies have administered nafamostat ERCP. So we investigated if infusion ERCP can affect post-ERCP (PEP) in high-risk patients. Methods In a tertiary hospital, 350 patients PEP were reviewed retrospectively. Among them, 201 received Patient-related and procedure-related risk factors for collected. We performed propensity score matching to...
Common bile duct (CBD) stones are prevalent in 11% to 21% of patients with gallstones and can cause various clinical manifestations, from biliary colic sepsis. The treatment choice is endoscopic retrograde cholangiopancreatography, but approximately 5% 10% CBD difficult remove using these conventional methods. Although percutaneous transhepatic cholangioscopy lithotripsy be used as an alternative, it technically demanding risky if the intrahepatic not dilated. We report a case large stone...